Advanced 3D models for metabolic disease research and drug efficacy testing
InSphero's 3D InSight™ Platforms provide comprehensive solutions for diabetes and NASH pathophysiology and drug discovery.
We are investigating metabolic disease pathophysiology and screening new drugs and treatments for type 1 and type 2 diabetes. Additionally, we monitor the progression of non-alcoholic fatty liver disease (NAFLD), from steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis.
Our robust and scalable 3D in vitro liver and islet disease models faithfully replicate human biology. This enables us to yield actionable insights into the progression and treatment of metabolic and liver diseases such as diabetes, NAFLD, or NASH.
InSphero Platforms
